AngioDynamics, Inc. (ANGO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$11.81-3.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · ANGO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.4% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 77.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 14 industry peers · Company calendar date is not available
ANGO — CEO transition
Dated 2026-10-08
CEO — James C. Clemmer: The CEO is retiring with a pre-announced, named external successor, representing an orderly succession rather than a sudden loss of leadership.
Why it matters: The RELIEF study tests NanoKnife for an enlarged prostate, beyond its cancer uses. A positive result could support this new use.
Supportive ifThe study reports a lower average symptom score at six months among its planned 40 patients.
Worry ifThe study fails to show a lower average symptom score at six months, or enrollment stops before 40 patients.
Why it matters: Med Tech is the main growth driver. A result below the 12% guidance floor would break the current growth trend.
Worry ifFY2027 Med Tech sales growth is below 12%, or management lowers its 12%–15% growth range.
Less concerning ifFY2027 Med Tech sales growth is at least 12%, and guidance stays at 12%–15%.
Why it matters: The full-year sales range sets a clear test for continued growth. Falling below it would weaken the growth case.
Worry ifFY2027 net sales come in below $336 million, or management cuts the $336M–$341M range.
Less concerning ifFY2027 net sales reach at least $336 million, and guidance stays at $336M–$341M.
Why it matters: First-quarter margin was 59.4%, helped by tariff refunds. Management says second-half margin will be lower.
Worry ifGross margin is below 54% in either half of FY2027, or full-year guidance falls below 54%.
Less concerning ifSecond-half gross margin is at least 54%, with full-year guidance still at 54%–55%.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$133 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $392 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,242 loss on $10,000 · 32.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.